Coronary artery disease (CAD) is prevalent in the CKD population. The methods of diagnosis are the same; however, the treatment parameters and strategies differ. This session focuses on strategies to halt the progression of CAD and a pharmacological plan of care for the patient with CAD and CKD.
Contact hours available until 9/22/2015.
Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation.
Conflict of Interest Disclosure:
Speaker(s) have no disclosures to declare.
Conference Committee Disclosures:
Dawn Koonkongsatian – Employee, Fresenius Medical Care
Kristin Larson – Employee, NxStage Medical
Denise Murcek – Employee, Fresenius Medical Care
Beth St. John - Employee, Fresenius Medical Care
Lucy Todd – Employee, Baxter Healthcare
Kyra Trappett – Employee, DaVita
Commercial Support and Sponsorship:
No commercial support or sponsorship declared.
Accreditation Statement:
American Nephrology Nurses’ Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
ANNA is a provider approved by the California Board of Registered Nursing, provider number CEP 00910.
Objectives:- Summarize the impact of coronary artery disease (CAD) on the person with CKD.
- Formulate treatment strategies to control the progression of CAD in the person with CKD.
- Generate a pharmacologic treatment plan for the person with CAD and CKD.